Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H18N6O4 |
Molecular Weight | 358.3519 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC(NC4=CC=CC=C4)=N1
InChI
InChIKey=SCNILGOVBBRMBK-SDBHATRESA-N
InChI=1S/C16H18N6O4/c17-13-10-14(21-16(20-13)19-8-4-2-1-3-5-8)22(7-18-10)15-12(25)11(24)9(6-23)26-15/h1-5,7,9,11-12,15,23-25H,6H2,(H3,17,19,20,21)/t9-,11-,12-,15-/m1/s1
Molecular Formula | C16H18N6O4 |
Molecular Weight | 358.3519 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
2-Phenylaminoadenosine (CV-1808) is an adenosine A2 receptor agonist. CV-1808 is a coronary vasodilator, antihypertensive and antipsychotic following systemic administration in vivo. CV-1808 appeared to be effective for salvaging ischemic myocardium. The effect might be related to improvement of coronary circulation and inhibition of release of vasoactive substances, including TXA2, from the ischemic myocardium. Development of CV-1808 has been discontinued in the United States.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800002475
Curator's Comment: # Takeda
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Correlation between binding affinities for brain A1 and A2 receptors of adenosine agonists and antagonists and their effects on heart rate and coronary vascular tone. | 1988 Dec |
|
Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. | 1989 |
|
Two phases of contractile response in rat isolated vas deferens and their regulation by adenosine and alpha-receptors. | 1989 Aug 29 |
|
Effects of adenosine A2 receptor agonists on nucleoside transport. | 1989 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6202970
Dogs: 2-Phenylaminoadenosine (0.25 ug/kg/min i.v. infusion throughout the experimental period, starting 10 min before coronary occlusion) inhibited coronary circulatory failure and TXA2 release.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2795461
Curator's Comment: A2 receptor activation was measured by the ability of the adenosine agonists to relax porcine coronary smooth muscle. Nucleoside transport was measured as the nitrobenzylthioinosine-sensitive cellular accumulation of [3H]uridine into guinea pig erythrocytes at 22 degrees C.
CV-1808 (2-phenylaminoadenosine) inhibited nucleoside transport with an EC50 of 140 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:59:27 GMT 2023
by
admin
on
Fri Dec 15 17:59:27 GMT 2023
|
Record UNII |
K40I59G1EF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
53296-10-9
Created by
admin on Fri Dec 15 17:59:27 GMT 2023 , Edited by admin on Fri Dec 15 17:59:27 GMT 2023
|
PRIMARY | |||
|
C026708
Created by
admin on Fri Dec 15 17:59:27 GMT 2023 , Edited by admin on Fri Dec 15 17:59:27 GMT 2023
|
PRIMARY | |||
|
DTXSID70967878
Created by
admin on Fri Dec 15 17:59:27 GMT 2023 , Edited by admin on Fri Dec 15 17:59:27 GMT 2023
|
PRIMARY | |||
|
6917803
Created by
admin on Fri Dec 15 17:59:27 GMT 2023 , Edited by admin on Fri Dec 15 17:59:27 GMT 2023
|
PRIMARY | |||
|
K40I59G1EF
Created by
admin on Fri Dec 15 17:59:27 GMT 2023 , Edited by admin on Fri Dec 15 17:59:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |